Brady Corporation — Form 10-Q Summary
Business context and period: Brady manufactures identification solutions and specialty materials, operating through the Americas, EMEA, and Asia-Pacific segments. This unaudited report covers the first quarter of fiscal 2013, the three months ended October 31, 2012, compared with the same quarter of fiscal 2012. Unless stated otherwise, amounts below are in U.S. dollars.
Financial results and liquidity
- Revenue: $337.6 million, down 3.4% from $349.5 million. Organic sales declined 1.9%; currency translation reduced sales 2.1%; acquisitions, net of divestitures, added 0.6%.
- Profitability: Gross profit was $164.6 million versus $167.8 million; gross margin improved to 48.8% from 48.0%. Operating income fell to $44.4 million from $49.1 million. Net income declined 16.9% to $27.2 million from $32.7 million. Diluted Class A EPS was $0.53 versus $0.62. Net margin was 8.1% versus 9.4%.
- Costs and taxes: R&D expense decreased to $8.5 million from $9.8 million. SG&A was $108.3 million versus $108.9 million, but rose to 32.1% of sales from 31.2%. The effective tax rate increased to 33.1% from 25.3%.
- Cash flow: Operating activities provided $20.2 million, versus $15.3 million. Investing activities provided $3.9 million, including $10.2 million of cash proceeds from divestitures, compared with $7.0 million used in the prior-year quarter. Financing activities used $12.7 million, primarily for dividends and share repurchases. Cash increased $15.4 million to $321.3 million.
- Balance sheet and debt: At October 31, cash was $321.3 million, current assets $692.5 million, and current liabilities $272.2 million. Debt carrying value was $321.0 million, including $61.3 million of current maturities; its estimated fair value was $343.9 million. The $300 million revolving credit facility was undrawn. Approximately 73% of cash was held outside the United States.
- Capital returns: Dividends paid were $9.7 million. Brady repurchased 188,167 shares for $5.1 million during the quarter and declared a subsequent quarterly dividend of $0.19 per share.
Changes versus the prior comparable quarter
- Sales declined across all three regions. Americas organic sales fell 0.7%, EMEA fell 3.2%, and Asia-Pacific fell 2.5%. Currency effects were particularly significant in EMEA, reducing sales 5.7%.
- Segment profit was $44.6 million in the Americas, up 3.2%; $23.6 million in EMEA, down 10.4%; and $12.1 million in Asia-Pacific, down 9.4%. Total reportable-segment profit declined 3.1% to $80.3 million.
- Interest expense declined to $4.2 million from $5.0 million, reflecting lower debt balances. Higher taxes and business-sale losses contributed to the net-income decline.
- Comprehensive income was $40.0 million versus $15.6 million, mainly reflecting a favorable foreign-currency translation adjustment in the current quarter; net income itself declined.
Management commentary, outlook, and risks
- Management cited continued global economic weakness. Priorities include growth in under-penetrated geographies and focus markets, new products, market-share gains, and expanded online sales to help offset traditional catalog declines.
- Brady sold its Brady Medical and Varitronics businesses as part of its strategy to focus on businesses with sustainable organic growth and profitability. The sales produced a combined pre-tax loss of $3.4 million; management reported a $3.2 million after-tax EPS impact of $0.06 per diluted Class A share.
- No quantified financial guidance or forecast is provided in the filing. Management said operating cash flow and borrowing capacity are expected to cover working capital, capital expenditures, restructuring, acquisitions, repurchases, debt repayment, and dividends.
- Debt covenants were met at quarter-end: debt to EBITDA was 1.5 to 1.0 against a 3.25 to 1.0 revolver limit, and interest coverage was 12.0 to 1.0 against a 3.0 to 1.0 minimum. The filing warns that repatriating foreign cash could create material expense.
- Key risks include prolonged economic weakness, foreign-exchange movements, market declines in hard disk drives and other served industries, competitive and pricing pressure, customer retention, product development, international operations, debt-covenant compliance, and potential intangible-asset write-downs. A 10% adverse currency move was estimated to reduce foreign net current assets by $40.7 million under the filing’s sensitivity assumptions.
- Restructuring charges of $12.1 million were recorded in fiscal 2012; $5.5 million remained accrued at October 31, 2012, with most remaining cash payments expected in fiscal 2013. Fiscal 2012 also included a $115.7 million goodwill impairment in the former North/South Asia reporting unit.
- Management concluded disclosure controls were effective at quarter-end and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether organic sales trends improve, particularly in EMEA, Direct Marketing, and Asia-Pacific Die-Cut markets.
- Whether margin gains from operational improvements and divestitures can offset lower sales and ongoing growth investment.
- The sustainability of operating cash flow and working-capital movements, including receivables and inventory.
- The impact of currency changes and the potential costs of accessing cash held outside the United States.
- Completion and financial effects of the divestitures, including the Varitronics promissory note and Brady Medical escrow consideration.
- Debt repayment, covenant headroom, future restructuring payments, and the carrying values of goodwill and other intangible assets.